Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

分组1 - Precision BioSciences reported a quarterly loss of $3.20 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.42, representing an earnings surprise of -661.90% [1] - The company posted revenues of $0.64 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 93.28%, compared to revenues of $7.04 million a year ago [2] - The stock has increased by approximately 33.6% since the beginning of the year, while the S&P 500 has declined by -1.8% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $10 million, and for the current fiscal year, it is -$1.05 on revenues of $45.6 million [7] - The Medical - Biomedical and Genetics industry is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]